M
Madeline Bertha
Researcher at Emory University
Publications - 9
Citations - 632
Madeline Bertha is an academic researcher from Emory University. The author has contributed to research in topics: Inflammatory bowel disease & Microbiome. The author has an hindex of 5, co-authored 7 publications receiving 397 citations.
Papers
More filters
Journal ArticleDOI
A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients
Andrew Brantley Hall,Andrew Brantley Hall,Moran Yassour,Moran Yassour,Jenny Sauk,Jenny Sauk,Ashley L. Garner,Ashley L. Garner,Xiaofang Jiang,Xiaofang Jiang,Timothy D. Arthur,Timothy D. Arthur,Georgia K. Lagoudas,Georgia K. Lagoudas,Tommi Vatanen,Tommi Vatanen,Nadine Fornelos,Nadine Fornelos,Robin G. Wilson,Madeline Bertha,Melissa Cohen,John J. Garber,Hamed Khalili,Dirk Gevers,Dirk Gevers,Dirk Gevers,Ashwin N. Ananthakrishnan,Subramaniam Kugathasan,Eric S. Lander,Eric S. Lander,Eric S. Lander,Paul C. Blainey,Paul C. Blainey,Hera Vlamakis,Hera Vlamakis,Ramnik J. Xavier,Curtis Huttenhower,Curtis Huttenhower +37 more
TL;DR: In this article, the authors performed metagenomic sequencing of monthly stool samples from 20 IBD patients and 12 controls (266 total samples) and identified strain-specific functional correlates with IBD outcomes.
Journal ArticleDOI
Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease
Kelly A Shaw,Madeline Bertha,Tatyana Hofmekler,Pankaj Chopra,Tommi Vatanen,Tommi Vatanen,Abhiram Srivatsa,Jarod Prince,Archana Kumar,Cary G. Sauer,Michael E. Zwick,Glen A. Satten,Aleksandar Kostic,Aleksandar Kostic,Jennifer G. Mulle,Ramnik J. Xavier,Ramnik J. Xavier,Subra Kugathasan +17 more
TL;DR: Patient dysbiosis improved over time but persisted even among those who responded to treatment and achieved mucosal healing, and it was found that pretreatment microbiome signatures are a promising avenue for prediction of remission and response to treatment.
Journal ArticleDOI
Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Tatyana Hofmekler,Madeline Bertha,Courtney McCracken,Benadette Martineau,Elizabeth McKinnon,Bess T. Schoen,Barbara O. McElhanon,Gayathri Tenjarla,Subra Kugathasan,Cary G. Sauer +9 more
TL;DR: It is demonstrated that low IFX levels are associated with development of immunogenicity to IFX as measured by ATI and early IFX level evaluation or primary initiation of Q6 week dosing be considered.
Journal ArticleDOI
Evolution of Pediatric Inflammatory Bowel Disease Unclassified (IBD-U): Incorporated With Serological and Gene Expression Profiles.
Raguraj Chandradevan,Tatyana Hofmekler,Kajari Mondal,Nusrat Harun,Suresh Venkateswaran,Hari K. Somineni,Cortney R. Ballengee,Mi-Ok Kim,Anne M. Griffiths,Joshua D. Noe,Wallace Crandall,Scott B. Snapper,Shervin Rabizadeh,Joel R. Rosh,Thomas D. Walters,Madeline Bertha,Marla Dubinsky,Lee A. Denson,Cary G. Sauer,James Markowitz,Neal S. Leleiko,Jeffrey S. Hyams,Subra Kugathasan +22 more
TL;DR: Results of the molecular and serological factors performed at the time of inflammatory bowel disease unclassified subjects' diagnosis suggests that they were very similar to UC, however, long-term studies are needed to better understand the natural history and molecular characterization of pediatric onset IBD-U.
Journal ArticleDOI
Trends in the inpatient burden of alcohol‐related liver disease among women hospitalized in the United States
TL;DR: While ALD remains predominantly male, discharges and mortality have disproportionately increased among women, particularly in young women and Native Americans, and these findings shed light on populations in need of intensive public health interventions.